Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume – Here’s What Happened

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares saw an uptick in trading volume on Thursday . 1,599,957 shares traded hands during trading, a decline of 16% from the previous session’s volume of 1,915,176 shares.The stock last traded at $33.3840 and had previously closed at $34.11.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday, July 22nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. HC Wainwright boosted their target price on shares of Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Finally, Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $39.50.

Genmab A/S Price Performance

The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $20.83 billion, a P/E ratio of 26.31, a PEG ratio of 1.96 and a beta of 0.83. The business’s 50 day moving average is $28.49 and its 200-day moving average is $27.92.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. As a group, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the company. Legacy Wealth Asset Management LLC increased its holdings in Genmab A/S by 164.1% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after purchasing an additional 63,484 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 16.4% during the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock valued at $109,000 after purchasing an additional 561 shares in the last quarter. Summitry LLC boosted its stake in shares of Genmab A/S by 5.3% during the first quarter. Summitry LLC now owns 11,170 shares of the company’s stock valued at $300,000 after purchasing an additional 567 shares in the last quarter. BankChampaign National Association bought a new stake in shares of Genmab A/S during the first quarter worth about $687,000. Finally, Strategic Investment Advisors MI bought a new stake in shares of Genmab A/S during the first quarter worth about $137,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.